BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- VVC Exploration Corporation, dba VVC Resources, ("VVC”), (TSX-V:VVC and ...
Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...
The suspected madman behind a deadly stabbing spree in Manhattan Monday has a long criminal history — and had just walked free from Rikers Island a month before the terrifying attacks, The Post ...
LRRK2 is the target of Biogen and Denali Therapeutics’ late-phase Parkinson’s disease asset BIIB122. Schrödinger has licensed a selection of its undisclosed discovery-stage programs to Novartis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback